We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Simple Blood Test for Esophageal Cancer Could Reduce Invasive Endoscopy Procedures

By LabMedica International staff writers
Posted on 22 Jun 2022

Barrett’s esophagus is a pre-malignant condition that occurs when the esophagus is damaged by acid reflux. More...

Barrett’s esophagus is asymptomatic and associated with an increased risk of esophageal cancer. Esophageal cancer is an area of significant unmet medical need, with current screening requiring specialist medical expertise. Now, a simple blood test targeted at patients with Barrett’s esophagus could detect biomarkers for esophageal adenocarcinoma that were already validated in a 300 patient study earlier this year.

Proteomics International (Perth, Australia) has secured an exclusive worldwide license to commercialize biomarkers that can test for esophageal adenocarcinoma, the most common form of esophageal cancer. The license agreement between Proteomics and the QIMR Berghofer Medical Research Institute (Queensland, Australia) was signed following a partnership between the two organizations to improve detection of the disease.

The QIMR Berghofer intellectual property in the biomarkers is licensed exclusively to Proteomics and will allow the company to use the biomarkers discovered by QIMR Berghofer researchers to develop and commercialize a simple blood test for esophageal adenocarcinoma. The license agreement comes after Proteomics and QIMR Berghofer validated the biomarkers in a joint study of more than 300 patients earlier this year. Proteomics will now undertake additional studies to confirm the diagnostic performance of the potential new blood test, which will take approximately six months and would be targeted at patients with Barrett’s esophagus.

“These at-risk patients are currently screened with invasive and costly endoscopy procedures. Instead, this panel of biomarkers - or protein ‘fingerprints’ in the blood - can detect the early stages of esophageal adenocarcinoma which we hope to do using a simple blood test,” said Dr. Richard Lipscombe, managing director of Proteomics International.

Related Links:
QIMR Berghofer 
Proteomics International 


New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Serological Pipet Controller
PIPETBOY GENIUS
New
Clinical Chemistry System
P780
New
8-Channel Pipette
SAPPHIRE 20–300 µL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: PD-1 protein blockade is the standard treatment for advanced melanoma among the different types of immunotherapy (Photo courtesy of 123RF)

Precision Tool Predicts Immunotherapy Treatment Failure in Melanoma Patients

Melanoma, though accounting for only about 4% of skin tumors, is the deadliest form of skin cancer due to its high potential to metastasize. While immunotherapy, especially PD-1 protein blockade, has revolutionized... Read more

Pathology

view channel
Image: Researchers have developed a novel method to analyze tumor growth rates (Photo courtesy of Adobe Stock)

Novel Method To Analyze Tumor Growth Rates Helps Tracks Progression Between Diagnosis and Surgery

Patients diagnosed with breast cancer often worry about how quickly their tumors grow while they wait for surgery, and whether delays in treatment might allow the disease to spread beyond the point of cure.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.